Diospyros kaki and Citrus unshiu Mixture Improves Disorders of Lipid Metabolism in Nonalcoholic Fatty Liver Disease
Table 1
The effect of PCM on body weight, liver weight, visceral fat weight, and food intake.
Group
Body weight (before drug treatment) Initial (g)
Body weight (drug treatment)
Liver weight (mg/g BW)
Food intake (g/day)
Calories of food intake (kcal/g)
Initial (g)
Final (g)
Gain (g/8 weeks)
Normal
22.06 ± 0.47
29.9 ± 0.6
31.8 ± 0.5
2.0 ± 0.3
59.6 ± 1.8
3.7 ± 0.2
14.2
HFD-fed mice
Veh
22.64 ± 0.39
43.3 ± 2.2
43.8 ± 2.4
0.5 ± 0.9
45.6 ± 3.1
2.7 ± 0.2
12.8
O60
22.82 ± 0.50
43.3 ± 2.1
37.6 ± 2.9
−5.7 ± 1.0
35.0 ± 1.3
3.1 ± 1.1
14.7
PCM50
22.77 ± 0.75
43.3 ± 1.5
42.7 ± 1.8
−0.6 ± 0.8
42.3 ± 1.3
2.6 ± 0.1
12.3
PCM100
22.75 ± 0.55
43.3 ± 1.5
42.5 ± 1.9
−0.8 ± 0.7
33.7 ± 2.1
2.6 ± 0.2
12.3
Calories per gram in normal diet add to 3.85 kcal/g, and calories per g in 45%. HFD is 4.73 kcal/g. Veh, HFD control mice; O60, orlistat 60 mg/kg-treated and obese mice; PCM50, PCM 50 mg/kg-treated and obese mice; PCM100, PCM 100 mg/kg-treated and obese mice. Data are the mean ± SEM, n = 7. Significance: < 0.05, < 0.01, and < 0.001 versus HFD control mice.
